REFERENCES
- Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics, 1973-98. Bethesda, MD, National Cancer Institute, 2001.
- Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993: 3; 255–68.
- Levin V, Leibel S, Gutin P. Neoplasms of the central nervous system, in De Vita V Jr, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997: 2022-82.
- Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585–92.
- Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer 2000; 82: 1371–80.
- Raymond E, Haon C, Boaziz C, et al. Logistic regres-sion model of fotemustine toxicity combining independent phase II studies. Cancer 1996; 78: 1980–7.
- Khayat D, Giroux B, SeriIle J, et al. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest. 1994; 12 (4): 414–20.
- Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 1985; 56: 1106–11.
- Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 1978; 49: 333–43.
- Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV: Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time—A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981; 47: 649–52.
- Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treat-ment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323–9.
- Gullu IH, Celik I, Tekuzman G, et al. Procarbazine, CCNU, vincristine combination in the treatment of brain tumors. Tumori 1996; 82: 228–31.
- Frenay M, Giroux B, Khoury S, Derlon JM, Namer M. Phase II study of fotemustine in recurrent supratentorial malig-nant gliomas. Eur J Cancer 1991; 27 (7): 852–6.
- Malhaire JP, Lucas B, Simon H, et al. Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull Cancer 1999; 86 (3): 289–94.
- Tortosa A, Vinolas N, Villa S, et al. Prognostic implica-tion of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003; 97 (4): 1063–71.